In 81 women with placenta-derived fetal growth restriction, daily enoxaparin plus standard care did not significantly reduce birthweight below the 10th percentile vs standard care alone (67.5% vs 73.2%; RR 0.92, 95% CI 0.69-1.23). Trial stopped early for poor recruitment.
RCTn = 81
Raia-Barjat et al. Enoxaparin for the treatment of placenta-derived fetal growth restriction (GROWTH): an open-label multicenter randomized trial